If you have searched for an alternative to PRP, IRAP, or stem cell therapy for a horse that is not responding to care, you have probably come across RenoVō®. It is a liquid, acellular equine amniotic tissue allograft that supplements and protects tissue, and it is showing up more often in ambulatory trucks and referral hospitals across the country.
Rather than describe RenoVō® in marketing language, we went straight to the veterinarians using it. Below are real answers from a survey of current RenoVō® users, organized by the questions horse owners and practitioners search most.
What Is RenoVō® and How Is It Different From PRP or Stem Cell Therapy?
RenoVō® is processed from amnion and amniotic fluid recovered during live birth, without harm to the mare or foal. Unlike PRP, IRAP, or autologous stem cells, it does not require drawing blood or tissue from the patient and waiting for it to culture or process. It ships frozen and is thawed at the clinic, so a vet can reach for it the same day a case presents.
Because it comes from screened donor tissue and is manufactured following stringent processes rather than the patient in front of them, the protein and growth factor profile is more consistent from dose to dose than patient-derived blood products, which can vary based on the animal and collection process. Independent laboratory testing comparing RenoVō® and PRP protein composition showed that RenoVō® exhibited a distinct biochemical profile characterized by markedly lower concentrations of measured pro-inflammatory cytokines (IFN-γ, IL-1α, IL-1β, and IL-15), higher concentrations of the endogenous IL-1 receptor antagonist (IL-1ra), elevated TIMP-2 concentrations, preserved α2-macroglobulin (A2M), and higher MCP-1 concentrations compared with PRP. Variability among RenoVō® production lots was relatively low compared to PRP samples (in-house data).
The product has been used in more than 35,000 horses to date.
RenoVō® is not FDA approved or USDA licensed. It is a tissue allograft processed under current Good Tissue Practices in a cleanroom environment, available by prescription and administered only by a licensed veterinarian.
What First Made Vets Want to Try RenoVō®?
We asked veterinarians what led them to try RenoVō® in their own practice. A few common threads came back: colleague referrals, conference lectures, and frustration with the limits of autologous options.
Tianti Askey, DVM, of Tianti Askey Royalty Equine, said: “I’ve seen it used successfully in practice and loved the results. I love the flexibility to use it how it’s needed on a case by case basis.”
Cody Dalton, DVM, of Elite Performance Equine Clinic, came to it through the literature: “After reading studies, appeared to be useful in our regenerative program.”
For the team at Beasley Equine Clinic, the appeal was practical as much as clinical: “The science and the ease of use (shelf stable in freezer).”
Josh Blyden, DVM, and Eric Bramow, DVM, of Interstate Equine Hospital, weighed it against the other allograft options on the market: “The fact it is an alternative to stem cell products at a reasonable price.”
Cathe Tallarico of Montall Vet Care traces her interest to a specific talk: “Amnion lecture at Hambletonian. I met Christian there.”
And for Chris Huth, DVM, one condition in particular got his attention: “The response to suspensory disease.”
Richard Rocconi, DVM, of Mid South Equine, summed up the operational case: “It allows our clinic to optimize patient care.”
Is RenoVō® Backed by Data, or Just Word of Mouth?
Both. Several respondents cited conferences and published studies as the reason they tried it in the first place. RenoVō® has been evaluated through prospective clinical studies, laboratory analyses, and published veterinary case reports across a range of orthopedic and soft tissue applications. The largest prospective multicenter field study followed 100 horses with 128 naturally occurring tendon and ligament injuries and found that 72% returned to or exceeded their previous level of work, with 92% of treating veterinarians reporting satisfaction. Additional studies have demonstrated the safety of intra-articular administration in equine joints. Independent third-party laboratory testing has also characterized RenoVō®’s biologic profile, including key anti-inflammatory and regenerative proteins. At the same time, word of mouth clearly matters in this field. Mike Black, DVM, of Nebraska Equine Clinic, and Jay Reynolds, DVM, both cited conversations with colleagues as what got them to try it, and several respondents mentioned meeting the RenoVō® team directly at events like the AAEP meeting or the Hambletonian.
How Do I Ask My Vet About RenoVō®?
If your horse has a case your current care plan is not resolving, ask your veterinarian whether RenoVō® is an option worth discussing. RenoVō® is prescription only and administered exclusively by licensed veterinarians, so it is not something an owner can order directly.
Veterinarians who want to review the case data, clinical study library, or become a RenoVō® customer can request information directly from the RenoVō® team.
Want to learn more? Explore RenoVō®’s clinical studies and case studies, or Contact Us today.
Results vary by patient and are not guaranteed. Always refer to the RenoVō® Instructions for Use and consult a licensed veterinarian before pursuing any care.
